PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

PEGS Boston – 17/02/2025
NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

Merck advantage grows as FDA approves Keytruda for first-line cervical cancer

Merck’s Keytruda is the dominant cancer immunotherapy and, of the seven of its type that are approved, the only that’s cleared for use in cervical cancer, the fourth most commonly diagnosed cancer in women in the U.S.

The study the latest approval is based on, a Phase 3 clinical trial called Keynote-826, proved that adding Keytruda to chemo and, if doctor’s chose, Avastin extended survival compared to those other drugs alone.

Detailed data showed that, among patients whose tumors expressed PD-L1, treatment with Keytruda reduced the risk of death by 36% and the risk of disease progression or death by 38%. A greater proportion of patients responded to treatment when Keytruda was added as well, and those responses lasted a median of about eight months longer.

Although Keynote-826 enrolled patients regardless of PD-L1 status, nearly 90% of participants had tumors that expressed the protein, a statistic that likely factored into the FDA’s decision to focus approval only for treatment of cancers that are PD-L1 positive.

According to Merck, Keytruda is the first new drug approved for use in front-line cervical cancer since the FDA cleared Avastin in 2014.

Other immunotherapies could soon join Keytruda as cervical cancer treatments, although Keytruda’s first-line OK will likely stand alone for some time.

Regeneron and partner Sanofi are awaiting an FDA decision by next January for their immunotherapy Libtayo as a second-line treatment, while Roche is studying two of its immunotherapies together.

The biotech Agenus, meanwhile, hopes to receive an OK from the regulator by December for its experimental drug balstilimab in second-line use.

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40